rss
Br J Ophthalmol 1995;79:1074-1077 doi:10.1136/bjo.79.12.1074
  • Research Article

Topical aldose reductase inhibitor for correcting corneal endothelial changes in diabetic patients.

  1. N Ohguro,
  2. M Matsuda,
  3. Y Ohashi and
  4. M Fukuda
  1. Department of Ophthalmology, Osaka University Medical School, Japan.

      Abstract

      BACKGROUND--Marked variations in cell size (polymegethism) and shape (pleomorphism) are characteristic of the corneal endothelium in diabetic patients and animals. METHOD--Wide field specular microscopy was used to evaluate the clinical efficacy of treating the diabetic corneal endothelium with topical instillation of 0.5% aldose reductase inhibitor, CT-112. RESULTS--Morphological variations (polymegethism and pleomorphism) of the endothelium in eight eyes from eight patients receiving CT-112 resolved within 3 months after initiation of treatment. In contrast, no change in endothelial morphology was noted in five eyes from five patients who received placebo. CONCLUSION--These observations suggest that aldose reductase may be involved in the aetiology of corneal endothelial variations in diabetic patients.

      This Article

      1. Abstract
      2. PDF

      Responses

      1. Submit a response
      2. No responses published

      Social bookmarking

      Register for free content


      Free sample
       This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
      View free sample issue >>

      Free archive
      The full back archive is now available for BJO. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
      Register to access the free archive >>

      Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.